Mirae Asset Pays First Monthly Dividend for 'Global Obesity Treatment ETF'... Event Held

Mirae Asset Global Investments announced on the 2nd that it will hold a customer appreciation event to celebrate the first monthly dividend payment of the ‘TIGER Global Obesity Treatment TOP2Plus Exchange-Traded Fund (ETF)’.

As of March 29, the ‘TIGER Global Obesity Treatment TOP2Plus ETF’ will pay a dividend of 15 KRW per share. This ETF is a monthly dividend type that pays dividends based on the last business day of each month. This is the first dividend payment since its new listing on the Korea Exchange on February 29.

Mirae Asset Global Investments will hold a monthly dividend ETF quiz event to commemorate the first dividend payment of the ‘TIGER Global Obesity Treatment TOP2Plus ETF’. Until April 8, among customers holding the ‘TIGER Global Obesity Treatment TOP2Plus ETF’, 100 people who answer the quiz correctly will be selected by lottery to receive gifticons. Detailed event information can be found on the TIGER ETF website.

The ‘TIGER Global Obesity Treatment TOP2Plus ETF’ focuses investments on ‘Eli Lilly’ and ‘Novo Nordisk’, which lead the global obesity treatment market. Eli Lilly, a manufacturer of obesity injection drugs, is currently the largest company by market capitalization in the global healthcare sector. Danish pharmaceutical company Novo Nordisk developed obesity treatments that have sparked a worldwide craze, becoming the leading stock in the entire European market.

Additionally, the ‘TIGER Global Obesity Treatment TOP2Plus ETF’ includes global listed companies related to the obesity treatment theme, such as Merck, AstraZeneca, Roche, Novartis, and Pfizer, which generate sales or are conducting research and development (R&D) in obesity treatments. These companies are expected to play an active role in the future obesity treatment market by utilizing surplus cash flow secured from their main commercialized products for mergers and acquisitions (M&A), licensing agreements, and more. Furthermore, their abundant cash flow can also be used as a resource for dividends to return value to shareholders.

Ha Min-jung, manager of the ETF management division at Mirae Asset Global Investments, said, “The TIGER Global Obesity Treatment TOP2Plus ETF invests in global big pharma companies with abundant financial resources, so investors can expect relatively high dividends while investing in an innovative growth theme.” She added, “The dividend yield of the underlying index of this ETF is around 1.9%, exceeding the dividend yield of 1.4% of the US market representative index, the S&P 500.”